Where We Choose to be Treated and Who Provides the Treatment Affects Our Chances Survival

How often have I said that when you are diagnosed with metastatic prostate cancer or when you experience a recurrence you need to move on to a specialist, a medical oncologist who specializes in the treatment of men with advanced prostate cancer? It is easier and more comfortable to stay with the known doctor, the [...]

Perineural Invasion On Prostate Biopsy: Does It Mean that I Have Advanced Prostate Cancer?

The simple answer is NO, however it should change your treatment game plan. A member of one of my support groups who has been doing active surveillance for about 5 years recently reported that their current biopsy indicated that they now have perineural invasion (PNI). They did not understand what was the significance of [...]

Do We Now Need To Question the Research Published in the NEJM?

A very interesting article appeared in the Saturday, November 24, 2012 edition of the Washington Post. According to the article The New England Journal of Medicine which is among the most prestigious medical journal in the world regularly features articles over which pharmaceutical companies and their employees exert significant influence. The problem is simple, over [...]

So, Where Is Your Evidence – Is Our Propensity to Believe the Folk Law Wasting our Time & Money

Having hot flashes because of hormone deprivation therapy (ADT)? All of us dealing with advanced prostate cancer will be on ADT, it is the usual first line of therapy and it will continue until we die. Men who elect to have radiation to treat prostate cancer as their primary treatment modality will often have some [...]

Coming in Early 2013 – A Genetic Test to Predict Which Prostate Cancers Need treatment and Which can be Subject to Active Surveillance

Genomic Health, Inc. has announced they have had positive results from a large clinical validation study of a biopsy-based prostate cancer test designed to predict adverse pathology in men with early prostate cancer. The study, performed in collaboration with prostate cancer researchers at the University of California, San Francisco (UCSF), met its primary endpoint by [...]

Go to Top